Consensus guidelines for the management and treatment of neuroendocrine tumors. Conference Paper uri icon

Overview

abstract

  • Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.

authors

  • Kunz, Pamela L
  • Reidy-Lagunes, Diane
  • Anthony, Lowell B
  • Bertino, Erin M
  • Brendtro, Kari
  • Chan, Jennifer A
  • Chen, Herbert
  • Jensen, Robert T
  • Kim, Michelle Kang
  • Klimstra, David S
  • Kulke, Matthew H
  • Liu, Eric H
  • Metz, David C
  • Phan, Alexandria T
  • Sippel, Rebecca S
  • Strosberg, Jonathan R
  • Yao, James C

publication date

  • May 1, 2013

Research

keywords

  • Neuroendocrine Tumors

Identity

PubMed Central ID

  • PMC4304762

Scopus Document Identifier

  • 84876840005

Digital Object Identifier (DOI)

  • 10.1097/MPA.0b013e31828e34a4

PubMed ID

  • 23591432

Additional Document Info

volume

  • 42

issue

  • 4